DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms

James Yao*,1,‡, Emily Bergsland2,‡, Rahul Aggarwal3, Ana Aparicio3, Himisha Beltran4, Judy S. Crabtree5, Christine L. Hann6,‡, Toni Ibrahim7, Lauren A. Byers8, Hironobu Sasano9, John Umejiego10, Marianne Pavel11

1Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
3The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
5Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA
6Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
7Oncotology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
8Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
9Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
10Amgen Inc., Thousand Oaks, CA, USA
11Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

*Corresponding author: James Yao, MD, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030-4017, USA. Tel: +1 713 792 2828; Email: jyao@mdanderson.org
‡Co-lead authors.

Abstract

Introduction: Neuroendocrine neoplasms (NEN) are heterogeneous malignancies that can arise at almost any anatomical site and are classified as biologically distinct well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Current systemic therapies for advanced disease, including targeted therapies, chemotherapy, and immunotherapy, are associated with limited duration of response. New therapeutic targets are needed. One promising target is delta-like ligand 3 (DLL3), an inhibitory ligand of the Notch receptor whose overexpression on the surface of NEN is associated with tumorigenesis.

Methods: This article is a narrative review that highlights the role of DLL3 in NEN progression and prognosis, the potential for therapeutic targeting of DLL3, and ongoing studies of DLL3-targeting therapies. Classification, incidence, pathogenesis, and current management of NEN are reviewed to provide biological context and illustrate the unmet clinical needs.

Discussion: DLL3 is overexpressed in many NENs, implicated in tumor progression, and is typically associated with poor clinical outcomes, particularly in patients with NEC. Targeted therapies using DLL3 as a homing beacon for cytotoxic activity mediated via several different mechanisms (eg, antibody-drug conjugates, T-cell engager molecules, CAR-Ts) have shown promising clinical activity in small-cell lung cancer (SCLC). DLL3 may be a clinically actionable target across NEN.

Conclusions: Current treatment options for NEN do not provide sustained responses. DLL3 is expressed on the cell surface of many NEN types and is associated with poor clinical outcomes. Initial clinical studies targeting DLL3 therapeutically in SCLC have been promising, and additional studies are expanding this approach to the broader group of NEN.

Key words: neuroendocrine tumors; neuroendocrine carcinoma; DLL3 protein, human; molecular targeted therapy.

Implications for Practice

Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors, most commonly located in the gastrointestinal tract, lung, bronchi, thymus, and pancreas. NENs are classified as well-differentiated neuroendocrine tumors (NET) or poorly differentiated neuroendocrine carcinomas (NEC). Targeted therapies, chemotherapy, and immune therapies have demonstrated clinical activity in NEN, but further improvements in response duration and survival are needed. Delta-like ligand 3 (DLL3) is overexpressed in many NENs, implicated in tumor progression, and associated with poor clinical outcomes, especially in patients with NEC. DLL3-targeting therapies are currently under clinical investigation, with promising antitumor activity demonstrated to date.
Introduction

Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors defined by National Comprehensive Cancer Network criteria as having traits of both endocrine and nervous system tissues, and World Health Organization criteria as being of epithelial or neuronal/neuroectodermal origin.\(^1,2\) NEN can form in almost every organ, but most commonly arise in the gastrointestinal tract, lung, bronchi, thymus, and pancreas.\(^3,5\) They are typically characterized by neurosecretory granules as well as histology and immunoprofiles/protein expression profiles, depending on differentiation.\(^2,5\) NEN are classified as well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC).\(^2,6\) This review describes NEN classification, incidence, pathogenesis, and current management, focusing on delta-like ligand 3 (DLL3) in NEN progression and prognosis. Therapeutic targeting of DLL3 is addressed, and ongoing studies of DLL3-targeting therapies are summarized.

Small-cell lung cancer (SCLC) is a poorly differentiated NEC, which is often discussed separately from other NEN because of differences in epidemiology, genetics, treatment, and prognosis.\(^1\) The disease state section of this review focuses on NEN other than SCLC, providing some discussion of SCLC when included in a given analysis. The sections on DLL3 prevalence and DLL3-targeting therapies specifically include SCLC, as much of the understanding of DLL3 as a therapeutic target originated in SCLC, thus providing context for targeting DLL3 in NEN.

Methods

The authors performed a narrative review of relevant academic English language literature. Levels of evidence were not assessed. The review is limited to published data and data presented at scientific congresses.

Overview of NEN

Classification

NET and NEC are biologically distinct, with different morphological characteristics, risk factors, genetics, and clinical aggressiveness.\(^2,5\) Essential features discriminating NET and NEC are histological tumor differentiation and grade, assessed by mitotic count and Ki-67 proliferation index (Table 1).\(^1,2,5,15\) NET are well differentiated and can range from low- to high-grade tumors. Grade 1 (G1) NET are defined as well-differentiated low-grade tumors; G2 NET are well-differentiated intermediate-grade tumors; G3 NET, most frequently occurring in the pancreas, are well-differentiated high-grade tumors with >20% proliferative activity or high mitotic rate.\(^1\) NEC are poorly differentiated and high-grade by definition. NEC are either large-cell (LCNEC) or small-cell NEC.

Mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN) also occur, having an aggressive course, with the non-neuroendocrine component frequently displaying as an adenocarcinoma or squamous cell carcinoma.\(^7,9\) In most MiNEN, the neuroendocrine and non-neuroendocrine components are poorly differentiated; the neuroendocrine component proliferates at rates similar to other NEC.\(^1,6\)

Treatment-emergent NEN describes those non-neuroendocrine cancers, such as prostate and lung cancers, that develop neuroendocrine features following treatment.\(^2\) NEN are rarely present at initial diagnosis, but targeted therapy may be associated with neuroendocrine transformation.\(^16-18\) Treatment-emergent neuroendocrine prostate cancers (NEPC) are most similar morphologically and genomically to poorly differentiated NEC and are typically characterized by small cells with prominent nuclei and rapid proliferation (small-cell carcinoma).\(^17,19,20\) The limited cytoplasm contains eosinophilic granules, hyperchromatic nucleus, and salt-and-pepper chromatin.\(^17,21\) Mixed histologies also can be observed.

Incidence

The 2012 US incidence of neuroendocrine tumors was estimated at 6.98 cases/100,000 people based on an analysis of data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registry.\(^3\) Common sites of NET vary according to race or ethnic group.\(^4,22\) Based on SEER data, Asian/Pacific Island and American Indian/Alaskan Native patients had a lower incidence of NET than White patients; African American patients had a higher incidence across all sites.\(^4\) Similarly, age-adjusted incidence rates of NET, particularly small intestinal and rectal, were significantly higher in the SEER African American population than in the SEER/Norwegian Registry of Cancer White population.\(^23\) Based on SEER data, Asian/Pacific Island and American Indian/Alaskan Native patients had a lower incidence of NEC than White and African American patients.

Most NEN commonly arises from gastroenteropancreatic (GEP) structures. A SEER study of GEP NECs found that 38% were in the colon, rectum, or anus, while 23% started in the pancreas. A SEER study of GEP NETs found the rectum to be the most common primary site followed by the small intestine and pancreas, while studies from Asia and Europe found different rank orders.\(^21\)

NEN are experienced by men and women at similar rates.\(^24\) However, primary NEN locations vary significantly by sex, with females more likely to have primary tumors in the lung, stomach, appendix, or cecum and males in the thymus, duodenum, pancreas, jejunum/ileum, or rectum.\(^4\)

Pathogenesis

Most NEN arise sporadically, typically as unifocal tumors, but 5-30% have an inherited component and are typically multifocal.\(^1,2,5,15\) NET and NEC can be distinguished by the genomic landscape in addition to histological features. Mutations associated with >7% of pancreatic NET include MEN1, DAXX, ATRX, PTEN, and genes in the mTOR signaling pathway.\(^2,27\) Clinically sporadic pancreatic NET have also been shown to be associated with germline mutations in DNA repair genes MUTYH, CHEK2, and BRCA2.\(^11,12,14\) Recurrent mutations for well-differentiated NETs of other sites have not been well defined, although significant enrichments in ACP, TP53, KRAS, or BRAF in NEC compared to G3 NET have been suggested as potential classifiers.\(^28\) Large-scale chromosomal instability is common, with chromatin-remodeling genes and subunits of the SWI/SNF complex mutated in 40% and >20% of pulmonary NETs, respectively.\(^29\) Specific patterns of chromosomal gain and loss appear to have independent prognostic values in NET subtypes.\(^30\) Mutations associated with NEC include TP53 or RB1 mutations, with KRAS and SMAD4 mutations also identified.\(^2,6,11\) BRAF mutations have been identified in colorectal NEN.\(^13\) In gastroenteropancreatic NEC
Table 1. Characteristics, classification, and grading criteria for NEN.12,26-35 Adapted from Nagtegaal et al.35

| Grade | NET, G1 | NET, G2 | NET, G3 | NEC, SCNEC | NEC, LCNEC | MiNEN |
|-------|---------|---------|---------|------------|------------|-------|
| Mitotic rate, mitoses/2 mm² | <2 | 2-20 | >20 | >20 | >20 | Variable |
| Ki-67 index, % | <3 | 3-20 | >20 | >20 | >20 | Variable |
| Differentiation | Well | Well | Well | Poorly differentiated | Poorly differentiated | Well or poorly differentiated |
| Additional characteristics | Produce secretory granules with high levels of neuroendocrine markers, and are characterized by well-developed “organoid” arrangements or neuroendocrine shape with nesting, trabecular, or gyriform/serpentine growth pattern | Characterized by a sheeple-like proliferation pattern, with cells that have irregular nuclei, high mitotic features, fewer cytoplasmic secretory granules, and low levels of neuroendocrine markers | Mixed neuroendocrine and non-neuroendocrine histology |
| Commonly associated mutations | MEN1, DAXX, PTEN, and ATRX, and mTOR family member signaling pathway mutations are observed in pancreatic NETs; NOTCH1 is absent or poorly expressed | TP53 or RB1 mutations May also have KRAS and SMAD4 mutations BRAF mutations in colorectal NEC | NOTCH1 and Hes1 expression is reduced or absent in the neuroendocrine cells, but both expressed in the adenomatous component The most frequent alterations occurred in TP53, RB1, PTEN, APC, PIK3CA, KRAS, BRAF, and MYC. |

Abbreviations: DLL3, delta-like ligand 3; LCNEC, large-cell neuroendocrine carcinoma; MiNEN, mixed neuroendocrine–non-neuroendocrine neoplasm; scanning magnification; the final grade is based on whichever of the 2 proliferation indexes places the neoplasm in the higher-grade category. The Ki-67 proliferation index value is determined by counting at least 500 cells in the regions of highest labelling (hot-spots), which are identified at scanning magnification; the final grade is based on whichever of the 2 proliferation indexes places the neoplasm in the higher-grade category. The Ki-67 proliferation index value is determined by counting at least 500 cells in the regions of highest labelling (hot-spots), which are identified at scanning magnification; the final grade is based on whichever of the 2 proliferation indexes places the neoplasm in the higher-grade category.

1Only includes gastrointestinal and pancreatic NETs.
2Poorly differentiated NEC are not formally graded, but are considered high-grade by definition.
3In most MiNENs, both the neuroendocrine and non-neuroendocrine components are poorly differentiated, and the neuroendocrine component has proliferation indices in the same range as other NECs; this MiNEN category allows for one or both components to be well differentiated; when feasible, each component should therefore be graded separately.
4Mitotic rates are to be expressed as the number of mitoses/2 mm² as determined by counting in 50 fields of 0.2 mm² (i.e., in a total area of 10 mm²).
5The Ki-67 proliferation index value is determined by counting at least 500 cells in the regions of highest labelling (hot-spots), which are identified at scanning magnification; the final grade is based on whichever of the 2 proliferation indexes places the neoplasm in the higher-grade category.

SCLC, molecular subtypes based on differential expression of ASCLI, NEUROD1, POU2F3, and other genes have been described.31–33 De novo neuroendocrine bladder cancers are strongly associated with mutations characteristic of neuroendocrine or small-cell cancers, such as SOX2, EZH2, and RB/p53 pathway mutations.34

In addition to the expression of NEN-associated markers, treatment-emergent NEPC is associated with decreased androgen receptor and/or prostate-specific antigen (PSA) expression.16,21,23,35 Transformed NEPC shares genomic features with prostate adenocarcinoma. RB1 and TP53 mutations are associated with the risk of transformation in prostate cancers and in a unique subset of EGFR-mutant lung cancers, with attenuated androgen receptor signaling through a reduction in androgen receptor splice variant 7 in castration-resistant NEPC.34,35 Preliminary evidence suggests lower rates of TMPRES-ERG gene fusions in NEPC than prostate adenocarcinoma.27 Mutations and/or copy number loss in DNA repair pathway genes were almost exclusive to treatment-emergent NEPC versus non–treatment-emergent tumors.35 Transformation of metastatic castration-resistant prostate cancer (CRPC) to treatment-emergent small-cell NEPC was associated with RB1 inactivation.35

Evolution and Prognosis

NET can evolve from G1 to G3 and eventually toward poorly differentiated NEC.39,41 Prognosis in patients with NEN varies by tumor type, stage and grade, and age at diagnosis. Generally, a worse prognosis is associated with tumors originating in the lung; those with liver, brain, or bone metastasis; higher grade/stage of tumor; and older age at diagnosis.3,42–44 Gastroenteropancreatic NET and NEC have differences in terms of prognosis; patients with gastroenteropancreatic NEC commonly develop distant metastasis, are characterized by rapid tumor growth, and have lower survival than patients with gastroenteropancreatic NET.45

Treatment-emergent NEC is associated with shorter survival and limited response to therapies.16,18 Treatment-emergent NEPC was associated with shorter median overall survival (OS) and progression-free survival (PFS) than mixed histology disease35 or metastatic CRPC.21

Current Management

Recommended treatments for NEN vary by subtype, stage/differentiation, and biologic characteristics.1,42,46 Herein, systemic therapies for advanced disease are described.

Somatostatin analogues have been used for symptomatic management of NENs47,48 and their antiproliferative effects.46,49,50 Octreotide and lanreotide, targeting somatostatin receptors (SSTR) 2 and 5, prolonged time to tumor progression or PFS in patients with well-differentiated midgut, hindgut, pancreatic, and G1/2 enteropancreatic NETs49,50; however, OS was not improved in long-term trials.50,51 In addition, lanreotide prolonged PFS and objective response rate (ORR) in patients with advanced bronchopulmonary NET.52 The radioabeled somatostatin analog, lutetium 177Lu dotatate (LUTATHERA), is approved for SSTR-positive gastroenteropancreatic NETs.53 177Lu dotatate plus standard-dose octreotide improved ORR (18%) and PFS compared to high-dose long-acting octreotide in patients with advanced midgut...
NETs after progression on somatostatin analogues, but not OS. Low or weak SSTR expression in many NEC and transient responses in SSTR-positive tumors could present challenges for [177]Lu dotate. The multi-tyrosine kinase inhibitor (TKI) sunitinib targets VEGFR 1-3 and is approved in patients with advanced, well-differentiated pancreatic NETs, providing improved PFS and an ORR of 9%, 57,58 A more recent TKI, surufatinib, was associated with improved PFS in extrapolancreatic and pancreatic NETs.59,62

The PI3K/Akt/mTOR pathway plays a critical role in NEN pathogenesis, and clinical trials of inhibitors that target this signaling axis support the promise of this approach.63 Everolimus is an approved therapy in adults with progressive gastrointestinal, pancreatic, and lung NETs, based on RADIANT-3 and -4 trials demonstrating PFS prolongation.64,66 In RADIANT-2, everolimus plus octreotide improved median PFS, narrowly missing statistical significance versus placebo plus octreotide.67,68 Currently, temozolomide-based chemotherapy and streptozotocin/5-FU are among the most well-established therapies for pancreatic well-differentiated NET and are associated with higher ORR than targeted agents.69,70 Platinum-based chemotherapy is standard-of-care for poorly differentiated NEC, but second- and third-line treatment options are limited and generally associated with short duration of response.71,72 Second-line options typically include the reintroduction of platinum chemotherapy and etoposide, irinotecan-based treatment (FOLFIRI),72 and oxaliplatin-based treatments (FOLFOX).73 The efficacy of second-line regimens is variable in G3 NET, although functional imaging and timing of G3 NET diagnosis may aid in treatment selection.41 FOLFOX has shown activity in poorly differentiated G3 NEC after cisplatinum-based chemotherapy and streptozotocin/5-FU74 compared with normal tissues. ASCL1 expression in SCLC is associated with DLL3 but negatively associated with Notch expression.94 Notch2 and DLL3 were upregulated in patients with adenocarcinoma, localized prostate adenocarcinoma.74 In high-grade NEC independent of the primary organ site, objective response was reported in 5/19 (26%) patients, with a clinical benefit rate of 32%.75 More recently, lower response rates were observed in a larger study in gastrointestinal pancreatic NEC and lung LCNEC (8 weeks: 14.9%).76 It remains unclear which patients benefit from immunotherapy.

Despite some improvement in outcomes, an unmet need exists for novel therapies with increased response durability and survival, particularly in highly proliferating G3 NEC with poor prognosis.

### DLL3 Signaling in NEN Tumorigenesis

#### Tumorigenesis of Notch1, DLL3 in NEN

The Notch pathway is a highly conserved cell signaling pathway that is implicated in malignant transformation, cell proliferation, cycle arrest, and apoptosis, epithelial to mesenchymal transition, and suppression of neuroendocrine differentiation.80 The Notch signaling pathway is initiated by the binding of one of five ligands (Jagged 1 [Jag 1], Jag 2, DLL1, DLL3, DLL4) with one of four receptors (Notch 1-4).80-82 The DLL family of proteins interact with EGF repeats on Notch receptors on cell membranes, triggering Notch signaling. In canonical Notch signaling, ligand binding results in the intracellular cleavage of the receptor by metalloproteases, and the Notch intracellular domain then translocates into the nucleus and modulates transcription of Notch-responsive genes.82 Notch signaling can be oncogenic or tumor suppressive depending on the cellular context. DLL1 has a tumor-suppressive role in lung cancer and is poorly expressed in the bone marrow of patients with lung cancer. In contrast, DLL1 has an oncogenic role in breast cancer, and its overexpression is associated with a poorer prognosis. DLL4 has an oncogenic role in a range of cancers.83 DLL3 is a noncanonical inhibitory ligand of the Notch receptor that is involved in NEC/NET tumorigenesis.84 DLL3 is thought to inhibit Notch signaling in cis; it does not bind or activate Notch receptors when presented in trans.85 In normal tissues, DLL3 is generally expressed at low levels (if at all) and confined to the cytoplasm.83,85 It regulates Notch signaling by preventing the localization of Notch receptors to the cell surface and redirecting them to the endosomes for degradation.85

#### DLL3 and Notch in Development of NEN

DLL3 expression is regulated by achaete-scute complex homolog 1 (ASCL1),83 a transcription factor that dictates neuroendocrine cell fate and whose expression correlates with tumor-initiating cell capacity.89 Upregulation of ASCL1 in RB1-mutated high-grade pulmonary NEC (SCLC and LCNEC) was associated with DLL3 overexpression compared with normal tissues. ASCL1 expression in SCLC is associated with DLL3 but negatively associated with Notch expression.90 DLL3 is expressed on the surface of tumor cells, in addition to having cytoplasmic localization.86,88 By modulating Notch1, DLL3 promotes migration and invasion in SCLC.91 Conversely, Notch pathway activation was associated with low neuroendocrine differentiation and increased intrinsic tumor immunity in SCLC cells.92 Both ASCL1 and DLL3 are highly expressed in NPEC. These were among the most differentially expressed Notch signaling genes in NPEC cells compared with adenocarcinoma, localized prostate adenocarcinoma, or benign cells.93 Additionally, upregulated DLL3 expression in patients with gastrointestinal or bladder/urinary tract NECs was strongly associated with ASCL1 expression.94 Notch2 and DLL3 were upregulated in patients with invasive versus non-invasive growth hormone–producing pituitary adenoma (P < .05).95

#### DLL3 and Inflammatory Biomarkers in NEN

The relationship between DLL3 expression and tumor immune environment may be complex. In consecutive surgically resected lung NEC, neoplasms with high DLL3 expression were often high-grade and more often displayed a moderate-to-severe inflammatory infiltrate than their low-expressing counterparts (65.6% vs. 27.7%).97 This inflamed state may suggest that T-cell-based therapies could have improved efficacy in these tumors. On the other hand, studies in SCLC found that DLL3 levels varied between transcriptional subtypes and were lowest in a subtype characterized by expression of numerous immune checkpoints and human leukocyte antigens, designated the SCLC-inflamed subtype (SCLC-I).32,33 The authors found that this inflamed subtype was associated with better responses to immune checkpoint blockade (ICB), raising the question of whether the patient
populations benefiting from ICB and DLL3-targeted therapies will be non-overlapping. A gene expression analysis in neuroendocrine bladder cancer (NEBC) found DLL3 expression to correlate with neuronal differentiation genes and high response rates in patients treated with atezolizumab. Surprisingly, immune pathway gene expression signatures normally enriched in tumors sensitive to immune checkpoint blockade were suppressed in these NEBCs. In total, these examples in differing neuroendocrine tumors highlight the need for further study of the immune system in DLL3-positive NEN. Future studies will be needed to determine if DLL3 expression correlates with expression of inflammatory biomarkers, if DLL3 has a role in immune infiltration into NENs, and whether DLL3 expression is prognostic for ICB response.

**DLL3 Expression in NEN**

Across nonneoplastic tissues, DLL3 expression is generally absent or low and confined to the cytoplasm. Numerous studies have established DLL3 mRNA and protein expression as features of NEN across several anatomic sites. DLL3 is particularly highly expressed in high-grade NETs and NECs, including on the tumor cell surface (described below). Representative prevalence of DLL3 by immunohistochemical (IHC) analysis according to NEN type and site is shown in Fig. 1 

**Prevalence in NET**

High DLL3 expression is frequently observed in high-grade NEN and less frequently in low-grade, well-differentiated NET. Of 155 patients with lung NET, high DLL3 was observed in 12.2% of typical and 24.4% of atypical carcinoids (ie, low-grade tumors). In 47 patients with gastroenteropancreatic NENs, DLL3 was detected in 76.9% of NECs, whereas DLL3 was absent in the 5 patients with G3 NET.

**Prevalence in NEC**

**Pulmonary NEC and SCLC**

DLL3 expression has been investigated extensively in SCLC. High DLL3 protein expression with localization to the cytoplasm and/or membrane was demonstrated by IHC analysis in patients with SCLC. Others reported DLL3 staining primarily in the Golgi apparatus and plasma membrane. High DLL3 expression was observed in the majority of patients with extensive-stage SCLC. Chinese patients with SCLC also had significantly higher DLL3 expression in SCLC tissue compared with matched para-nocancerous tissues. Analyses from clinical trial populations demonstrate that DLL3 is expressed in >75% of SCLC.

LCNEC is associated with high DLL3 expression. In patients with LCNEC, 26/70 (37.1%) were DLL3 positive. The disease was stage I in 15 and 26 DLL3-positive and negative patients, respectively; stage II in 4 and 11; and stage III in 7 and 7 patients. By IHC analysis, DLL3 expression was observed in 82% of 45 patients with SCLC, LCNEC, or neuroendocrine carcinoma with mixed histology. A high percentage (75%) of stage IV LCNEC shows DLL3 expression, with the majority being cytoplasmic. Similarly, IHC analysis of 73 patients revealed high DLL3 expression in 54% of patients with LCNEC and 75% with SCLC.

**NEPC**

DLL3 is expressed in NEPC. DLL3 was expressed in most patients with castration-resistant NEPC (n = 36/47 [76.6%]), but only a subset of those with CRPC adenocarcinoma (n = 7/56 [12.5%]). Another study using 21 NEPC tumor samples reported 16 (76%) were DLL3-positive.

**Other NEC**

DLL3 expression was demonstrated in gastroenteropancreatic, bladder, and cervical NEN. In a retrospective study of 47 patients, DLL3 was expressed on 76.9% of poorly differentiated gastroenteropancreatic NEC; DLL3 expression correlated with R1 loss (P < .001), a negative Ga-PET/CT scan (P = .001), and an unfavorable clinical outcome. In transcriptomic and protein analyses of 63 patients with small-cell bladder cancer, 79% had increased small-cell component (>50%), and DLL3 and CD56 protein expression (>1% of tumor cells) was 68% and 81%, respectively, in 53 patients with available samples. Similarly, samples from patients with neuroendocrine bladder cancer showed strong enrichment with biomarkers characteristic of neuroendocrine or small-cell malignancies, including DLL3. In patients with NEC of the cervix, DLL3 expression was found in 81% and was inversely correlated or mutually exclusive with other commonly observed mutations. DLL3 expression was upregulated in 49% of patients with extra-pulmonary NEC (gastrointestinal tract, n = 4; bladder, n = 7). All patients with Merkel cell carcinoma (MCC; ~90%) had DLL3 expression, with over half having ≥50% tumor cells positive for DLL3 expression.

DLL3 overexpression was also observed in patients with growth hormone–producing pituitary adenoma, with DLL3 more highly expressed in invasive versus non-invasive tumors. Similarly, in medullary thyroid carcinoma, DLL3 expression correlated with stromal desmoplasia and lymph node metastases, and may indicate aggressive disease. In DLL3-high tumors, protein distribution was primarily membranous; localization in DLL3-low tumors was primarily cytoplasmic.

**Clinical Implications of DLL3 in NEN**

High DLL3 expression is primarily associated with various NEC and extensive/late-stage disease and is negatively correlated with survival in most studies. Recent analysis of 155 samples of lung NENs found high DLL3 expression was more common in patients who smoked (current/former) and was associated with peripheral tumors.
(\(P = .001\)) and disease-free survival (DFS; \(P < .01\)). DLL3 expression correlated with other features associated with high-grade NEC (ie, high mitosis number, Ki-67 index, and necrosis). In 76 patients with growth hormone−producing pituitary adenoma, low DLL3 expression was associated with significantly longer DFS compared with high DLL3 expression (\(P = .027\)). In patients with small-cell bladder cancer, low protein expression of both CD56 (≤30%) and DLL3 (≤10%) was associated with a longer median OS (103.4 vs. 18.4 months, \(P = .01\)) and PFS (92.2 vs. 11.4 months, \(P = .02\)) relative to patients with high expression of either biomarker. \(P = .36; 5\)-year RFS, 41.7% vs. 35.7%, \(P = .74\). In contrast, in those with DLL3-negative tumors, a significantly greater 5-year OS and RFS was observed for patients treated with versus without adjuvant chemotherapy (5-year OS, 90.0% vs. 26.9%, \(P < .01\); 5-year RFS, 80.0% vs. 21.7%, \(P < .01\)).

### DLL3-Targeting Therapies

Several different DLL3-targeting modalities are being pursued, including antibody-drug conjugates (ADC), T-cell engagers, and chimeric antigen receptor (CAR) T cells. Preclinical and clinical experience with some of these agents is summarized here.
Despite its development being terminated, Rova-T, an ADC consisting of a DLL3-targeting monoclonal antibody, cathepsin-cleavable linker, and pyrrolobenzodiazepine (PBD) warhead, demonstrated the potential of targeting DLL3. Preclinical efficacy of Rova-T in combination with the mTOR inhibitor everolimus was demonstrated in pancreatic and bronchial NEN cell lines. The first-in-human clinical trial of Rova-T in recurrent SCLC found an overall ORR of 18% in evaluable patients and 38% in patients with high DLL3 expression despite often severe side effects attributable to the PBD warhead. However, in the phase II TRINITY study, Rova-T did not demonstrate differential benefits in DLL3-positive disease versus the overall population.

A phase I/II study of Rova-T was conducted in 101 patients with NEN (pulmonary and extrapulmonary LCNEC, n = 13; high-grade gastroenteropancreatic NEC, n = 36; NEPC, n = 21; pooled other NEC/NET, n = 31) and 99 patients with other solid tumors (melanoma, n = 20; medullary thyroid cancer, n = 13; glioblastoma, n = 23; other solid tumors, n = 43). Overall, confirmed responses were reported for 10% of patients treated at 0.3 mg/kg, including 13% with NEC/NET; the median PFS and OS were 4.1 (95% CI, 2.8-4.8) and 7.1 (95% CI, 5.6-9.7) months, respectively. Median PFS and OS were 4.3 (95% CI, 2.7-6.1) and 7.4 (95% CI, 5.6-13.1) months in patients with high DLL3 expression, and 3.3 (95% CI, 2.4-4.8) and 7.1 (95% CI, 4.3-9.9) months among patients with low DLL3 expression. Similarly, treatment with Rova-T did not provide benefit compared with topotecan in the second-line setting for SCLC or as maintenance after induction etoposide/platinum in the first-line setting.

Another DLL3-targeting ADC, SC-002, was designed to reduce the toxicity observed with Rova-T. In a phase Ia/Ib study in 35 patients with relapsed and/or refractory SCLC or LCNEC, 5 patients (14%) achieved a partial response as the best overall response; however, the toxicity profile of SC-002 prevented further development.

The toxicities of Rova-T and SC-002 were primarily attributed to the cytotoxic warhead, suggesting that DLL3 remained a compelling target. Indeed, the DLL3-targeting bispecific T-cell engager (BiTE) molecule tarlatamab (AMG 757) has shown promising clinical activity, and the DLL3-targeting T-cell–engaging agents BI 764532 and HPN328 are under clinical investigation (Table 2).

Table 2. Select ongoing clinical trials of DLL3-targeting therapies

| Treatment   | Study ID         | Tumor type                  | Target enrollment, n | Phase (status)  |
|-------------|------------------|-----------------------------|----------------------|-----------------|
| Tarlatamab  | NCT03319940      | SCLC                        | 382                  | Phase I (recruiting) |
|             | NCT04702737      | NEPC                        | 60                   | Phase I (recruiting) |
|             | NCT04885998      | SCLC                        | 50                   | Phase I (recruiting) |
|             | NCT05060016      | SCLC                        | 160                  | Phase II (recruiting) |
| BI 764532   | NCT04429087      | SCLC and other NEN          | 110                  | Phase I (recruiting) |
| HPN328      | NCT04471727      | SCLC and other high-grade NET | 57                  | Phase III (recruiting) |

Abbreviations: DLL3, delta-like ligand 3; NEC, neuroendocrine carcinoma; NEPC, neuroendocrine prostate cancer; SCLC, small-cell lung cancer.
BI 764532 is a DLL3-targeting T-cell–engaging bispecific antibody shown to selectively bind DLL3 on tumor cells and CD3 on T cells, resulting in T-cell activation and directed lysis of SCLC cells in vitro. Treatment with BI 764532 resulted in infiltration of T cells into tumor tissue and tumor regression in xenograft models. BI 764532 is being studied in phase I in patients with DLL3-expressing SCLC, LCNEC, or other NEC or small-cell carcinoma of any other origin. HPN328 is a tri-specific T-cell–activating construct that consists of 3 binding domains, namely, CD3 on T cells, DLL3 on tumor cells, and human serum albumin to extend half-life. HPN328 mediated T-cell cytotoxicity against target cells in a dose- and DLL3-dependent manner. A phase I/II study in patients with DLL3-expressing SCLC, Lung Cancer, or other NEC or small-cell carcinoma of any other origin. 

The Oncologist, 2022, Vol. 27, No. 1

Conclusions

NENs are a heterogeneous group of tumors most commonly located in the gastrointestinal tract, lung, bronchi, thymus, and pancreas. They are classified based on histology and grading as well-differentiated NET or poorly differentiated NEC. Though targeted therapies, chemotherapy, and, to a limited extent, immunotherapies confer some clinical benefit to patients with NEN, a need remains to identify new treatments associated with more sustained responses and improved survival particularly for high-grade (G3) NET and NEC. The recognition that DLL3 is enriched in high-grade NENs and associated with worse clinical outcomes opens these challenging tumors up to the promise of DLL3-targeting agents, some of which have already demonstrated clinical antitumor activity.

Acknowledgments

The authors thank Miranda Tradewell, Erin P. O’Keefe, Lisa Denny, Lee Hohaia (ICON, Blue Bell, PA), and Eugene Gillespie (Amgen Inc.), whose work was funded by Amgen Inc., for medical writing assistance in the preparation of this manuscript.

Funding

This study was sponsored and funded by Amgen Inc.

Conflict of Interest

James Yao: Hutchmed, Ipsen, Amgen, Chiasm (C/A); Emily Bergsland: Amgen, RayzeBio, Hutchmed, Advanced Accelerator Applications (C/A [unpaid]), Merck (RF [institutional]); Rahul Aggarwal: Clovis Oncology (H), Dendreon, Advanced Accelerator Applications, Clovis Oncology, Axiom Biotechnologies, AstraZeneca, Pfizer, Merck, Amgen, Jublant Pharmaceuticals, Alessa Therapeutics (C/A), Zenith Epigenetics, Novartis, Xynomic Pharma, Cancer Targeted Technology, Janssen, Merck, AbbVie, Amgen, AstraZeneca, BioXcel Therapeutics (RF [institutional]); Ana Aparicio: Astellas, Janssen (C/A), American Cancer Society (education services); Himisha Beltran: Janssen, Astellas, AstraZeneca, Merck, Pfizer, Foundation Medicine, Blue Earth Diagnostics, Oncorus, Amgen (C/A), Janssen, AbbVie/Stemcentrx, Eli Lilly, Millennium Pharmaceuticals, Bristol Myers Squibb (RF), Amgen, Oncentral (SAB); Judy S. Crabtree: Amgen (SAB); Christine L. Hann: Janssen, AstraZeneca (C/A), Amgen, AbbVie, BMS, Genentech (RF [institutional]), Amgen (SAB); Toni Ibrahim: Amgen, Pharmamar (H, SAB); Lauren A. Byers: AstraZeneca, GenMab, Sierra Oncology, PharmaMar, AbbVie, Bristol Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals, Genentech, Debiopharm Group (C/A), AstraZeneca, GenMab, Sierra Oncology, Toler Pharma (RF); Hironobu Sasano: Novartis Oncology Japan, Teijin Pharm Co. Ltd., Nobel Pharma Co. Ltd. (RF, H); John Unejiego: Amgen (E, OI); Marianne Pavel: AAA, Ipsen, Novartis, Amgen, Lilly, Riemsler (C/A), MSD, Boehringer Ingelheim, AAA, Ipsen, Novartis, Lilly (H), AAA, Crinetics (SAB).

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.

Author Contributions

Data analysis and interpretation, manuscript writing, and final approval of manuscript: All authors.

Data Availability

No data were generated for this article; published references are cited at the end of the article.

References

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. 2021. NCCN.org. Accessed June 24, 2021.
2. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770-1786. https://doi.org/10.1038/s41379-018-0110-y.
3. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-1342. https://jamanetwork.com/journals/jamaoncology/fullarticle/2621997.
4. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
5. Kloppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Vac Med. 2017;33:324-330. https://doi.org/10.1159/000481390.
6. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182-188. https://doi.org/10.1111/his.13975.
7. La Rosa S, Uccella S. Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord. 2021;22:527-538.
8. Frizziero M, Chakrabarty B, Nagy B, et al. Mixed neuroendocrine non-neuroendocrine neoplasms: a systematic review of a controversial and underestimated diagnosis. J Clin Med. 2020;9.
9. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading as well-differentiated NET or poorly differentiated NEC. The Oncologist, 2020;25:527-538.
10. Oronsky B, Ma PC, Morgenstern D, et al. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991-1002. https://doi.org/10.1016/j.neo.2017.09.002.
11. van Arx C, Capozzi M, López-Jiménez E, et al. Updates on the role of molecular alterations and NOTCH signalling in the development of neuroendocrine neoplasms. J Clin Med. 2019;8.

12. van Riet J, van de Werken HJG, Cuppen E, et al. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun. 2021;12:4612. https://doi.org/10.1038/s41467-021-24812-3.

13. Corbo V, Dalai I, Scardoni M, et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer. 2010;17:771-783. https://erc.biomedcentral.com/view/journals/erc/17/3/771.xml.

14. Scarp a A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65-71. https://doi.org/10.1038/nature21063.

15. Olevian DC, Nikiforova MN, Chiose a S, et al. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016;49:124-134. https://doi.org/10.1016/j.humpath.2015.11.004.

16. Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492-2503. https://ascopubs.org/doi/10.1200/JCO.2017.77.6880.

17. Clermont P-L, Ci X, Pandhi H, et al. Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. Int J Endocr Oncol. 2019;6:1JE20.

18. Aggarwal RR, Feng FY, Small EJ. Emerging categories of disease in advanced prostate cancer and their therapeutic implications. Oncology (Williston Park). 2017;31:467-474.

19. Cejas P, Xie Y, Font-Tello A, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12:5775. https://doi.org/10.1038/s41467-021-26042-z.

20. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756-767. https://journals.lww.com/ajsp/Abstract/2014/06000/Proposed_Morphologic_Classification_of_Prostate.3.aspx.

21. Zhang Q, Han Y, Zhang Y, et al. Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol. 2020;10:571308. https://doi.org/10.3389/fonc.2020.571308.

22. Hauso O, Gustafsson BI, Kild M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655-2664. https://doi.org/10.1002/cncr.23883.

23. Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43-43. https://doi.org/10.1007/s11912-021-01029-7.

24. Leoncini E, Boffetta P, Shafir M, et al. Increased incidence trend of neuroendocrine tumors: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019;26:391-403. https://doi.org/10.1530/ERC-18-0332.

25. Kawasaki K, Toshimitsu K, Matano M, et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell. 2020;183:1420-1435.e21. https://doi.org/10.1016/j.cell.2020.10.023.

26. Fernandez-Cuesta I, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5:3518. https://doi.org/10.1038/ncomms4518.

27. Yao J, Garg A, Chen D, et al. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019;26:391-403. https://doi.org/10.1530/ERC-18-0332.

28. Rudin CM, Pozier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289-297. https://doi.org/10.1038/s41568-019-0133-9.

29. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.e7. https://doi.org/10.1016/j.ccell.2020.12.014.

30. Van Riet J, van de Werken HJG, Cuppen E, et al. The genomic landscape of pancreatic neuroendocrine tumors. Nature. 2017;543:65-71. https://doi.org/10.1038/nature21063.

31. Olevian DC, Nikiforova MN, Chiose a S, et al. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016;49:124-134. https://doi.org/10.1016/j.humpath.2015.11.004.

32. Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492-2503. https://ascopubs.org/doi/10.1200/JCO.2017.77.6880.

33. Clermont P-L, Ci X, Pandhi H, et al. Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. Int J Endocr Oncol. 2019;6:1JE20.

34. Aggarwal RR, Feng FY, Small EJ. Emerging categories of disease in advanced prostate cancer and their therapeutic implications. Oncology (Williston Park). 2017;31:467-474.

35. Cejas P, Xie Y, Font-Tello A, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12:5775. https://doi.org/10.1038/s41467-021-26042-z.

36. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756-767. https://journals.lww.com/ajsp/Abstract/2014/06000/Proposed_Morphologic_Classification_of_Prostate.3.aspx.

37. Zhang Q, Han Y, Zhang Y, et al. Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol. 2020;10:571308. https://doi.org/10.3389/fonc.2020.571308.

38. Hauso O, Gustafsson BI, Kild M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655-2664. https://doi.org/10.1002/cncr.23883.

39. Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43-43. https://doi.org/10.1007/s11912-021-01029-7.

40. Jensen RT, Bodei L, Capdevila J, et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2019;108:26-36. https://doi.org/10.1159/000494258.

41. Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:484-494. https://www.acpjournals.org/doi/10.7326/0003-4819-129-6-19980915-00011.

42. Xiao Q, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203. https://doi.org/10.1126/science.1200609.

43. Venizelos A, Elebafakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021;29:1-14. https://doi.org/10.1530/ERC-21-0152.
perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology*. 2017;105:245-254. https://doi.org/10.1159/000461583.

47. Rubin J, Aajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *J Clin Oncol*. 1999;17:600-606. https://doi.org/10.1200/JCO.1999.17.2.600.

48. Fisher GA Jr., Wolin EM, Liyanage N, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autoinjector: results from a randomized, placebo-controlled, double-blind and 32-week open-label study. *Oncologist*. 2018;23:16-24. https://doi.org/10.1634/theoncologist.2017-0284.

49. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PRO-MID Study Group. *J Clin Oncol*. 2009;27:4656-4663. https://doi.org/10.1200/JCO.2009.22.8510.

50. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med*. 2014;371:224-233.

51. Rinke A, Gress TM. Neuroendocrine cancer, therapeutic strategies in G3 cancers. *Digestion*. 2017;95:109-114. https://doi.org/10.1159/0004545761.

52. Horsch D, Baudin E, Singh S, et al. Lanreotide autoalgel depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETS): results from the phase III SPINET study. *Ann Oncol*. 2021;32:s906-s920.

53. LUTATHERA® (lutetium Lu 177 dotatate). *Full Prescribing Information, Advanced Accelerator Applications USA*, Inc., NJ; 2021.

54. Strosberg JR, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. *N Engl J Med*. 2017;376:125-135. https://doi.org/10.1056/NEJMoa1607427.

55. Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-dotate plus everolimus plus octreotide long-acting repeatable for advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet*. 2011;378;2005-2012. https://doi.org/10.1016/S1470-2045(11)61742-X.

56. Pavie ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 trial. *J Clin Oncol*. 2017;35:2007-2015. https://doi.org/10.1200/JCO.2016.71.7935.

57. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors: overall survival from a phase III randomized study. *Ann Oncol*. 2009;20:1867-1875. https://doi.org/10.1093/annonc/mdp110.

58. Roodbol FM, den Heijer T, Paulus W, et al. Sunitinib plus octreotide with or without everolimus in patients with advanced pancreatic neuroendocrine tumors: a randomized, placebo-controlled, phase 3 trial. *Clin Cancer Res*. 2016;22:657-664. https://doi.org/10.1158/1078-0432.CCR-15-0119.

59. Konishi Y, Sato N, Chiba S, et al. Sorafenib in patients with advanced pancreatic neuroendocrine tumors. *Gastroenterology*. 2014;146:1304-1315. https://doi.org/10.1053/j.gastro.2013.12.021.

60. Yamada T, Yamashita K, Tanaka E, et al. Sunitinib in advanced neuroendocrine tumors: an exploratory biomarker analysis. *Ann Oncol*. 2016;27:1171-1177. https://doi.org/10.1093/annonc/mdw311.

61. Hainaut P, Prezioso V, Larsson D, et al. Sunitinib versus placebo in patients with advanced pancreatic neuroendocrine tumors treated with lanreotide: results from the French randomized, placebo-controlled phase III STOP study. *Clin Cancer Res*. 2018;24:3174-3182. https://doi.org/10.1158/1078-0432.CCR-17-2308.

62. Xu J, Shen L, Bai C, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. *Eur J Cancer*. 2015;51:1253-1262. https://doi.org/10.1016/j.ejca.2015.04.005.

63. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capcitabine in patients with metastatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). *J Clin Oncol*. 2018;36:4004-4007.

64. Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. *Endocr Relat Cancer*. 2015;22:657-664. https://doi.org/10.1530/ERC-15-0019.

65. Kusunoki K, Hori S, Goto Y, et al. Sunitinib in patients with advanced pancreatic neuroendocrine tumors: a phase II trial of sunitinib and temozolomide in patients with advanced pancreatic neuroendocrine tumors (NEJ030): a phase II trial of sunitinib and temozolomide in patients with advanced pancreatic neuroendocrine tumors (NEJ030). *Ann Oncol*. 2014;25:1172-1177. https://doi.org/10.1093/annonc/mdu300.

66. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med*. 2011;364:514-523. https://doi.org/10.1056/NEJMoa1009290.

67. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet*. 2016;387:968-977. https://doi.org/10.1016/S0140-6736(15)00817-X.

68. AFINITOR®/AFINITOR DISPERZ® (everolimus/everolimus tablets for oral suspension). Full Prescribing Information, Novartis Pharmaceuticals Corporation, NJ; 2021.

69. Patel S, Mervenson E, Chae YK, et al. Phase II basket trial of double anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. *Clin Cancer Res*. 2020;26:2290-2296. https://doi.org/10.1158/1078-0432.CCR-19-3356.

70. Patel S, Muller P, Kung AL, et al. Phase I dose escalation study of double anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG S1609: high-grade neuroendocrine neoplasm cohort). *Clin Cancer Res*. 2021;27:3194-3201. https://doi.org/10.1158/1078-0432.CCR-20-0621.

71. Girard N, Mazieres J, Otto J, et al. LBA41 – Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors. *Clin Cancer Res*. 2017;23:4625-4632. https://doi.org/10.1158/1078-0432.CCR-16-3135.

72. Klein O, Kee D, Markman B, et al. Immunotherapy of ilipimub and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers. *Clin Cancer Res*. 2020;26:4454-4459. https://doi.org/10.1158/1078-0432.CCR-20-0621.
neuroendocrine tumors (NECs) (GCG-001 NIPINEC). Ann Oncol. 2021;32:S1283-S1346.

80. Leonetti A, Facchinetti F, Minari R, et al. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol (Dordr). 2019;42:261-273. https://doi.org/10.1007/s13402-019-00441-3.

81. Crabtree JS, Miele L. Neuroendocrine tumors: current therapies, notch signaling, and cancer stem cells. J Cancer Metastasis Treat. 2016;2:279-293.

82. Crabtree JS, Singleton CS, Miele L. Notch signaling in neuroendocrine tumors. Front Oncol. 2016;6:94. https://doi.org/10.3389/fonc.2016.00094.

83. Xiu MX, Liu YM, Kuang BH. The role of DLLs in cancer: a novel therapeutic target. Oncos Targets Ther. 2020;13:3881-3901. https://doi.org/10.2147/OTT.S244860.

84. Ladi E, Nichols JT, Ge W, et al. The divergent DSL ligand DLL3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170:983-992. https://doi.org/10.1083/jcb.200503113.

85. Chapman G, Sparrow DB, Kremmer E, et al. Notch inhibition by the ligand Delta-3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet. 2011;20:905-916. https://doi.org/10.1093/hmg/ddq529.

86. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.

87. Sharma SK, Pourat J, Abdel-Atti D, et al. Noninvasive interrogation of DLL3 expression in metastatic small cell lung cancer. Cancer Res. 2017;77:3931-3941. https://doi.org/10.1158/0008-5472.CAN-17-0299.

88. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537. https://doi.org/10.1158/1078-0432.CCR-20-2845.

89. Dylla SJ. Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse. Mol Cell Oncol. 2016;3:e1101515. https://doi.org/10.1080/23723556.2015.1101513.

90. Tendler S, Kanter L, Lewensohn R, et al. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS One. 2020;15:e0240973. https://doi.org/10.1371/journal.pone.0240973.

91. Furuta M, Sakakihara JK, Shoji T, et al. DLL3 regulates migration and invasion of small cell lung cancer. Cancer Res. 2018;78.

92. Roper N, Velez MJ, Chiappori A, et al. Notch signaling and efficacy of PD-1/PD-1 blockade in relapsed small cell lung cancer. Nat Commun. 2021;12:3880. https://doi.org/10.1038/s41467-021-24164-y.

93. Puca L, Gavert K, Sailer V, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11.

94. La Salvia A, Rapa I, Metovic J, et al. Extra-pulmonary neuroendocrine carcinomas display distinct transcriptional profiles according to the site of origin. Neuroendocrinology. 2019;108:29.

95. Feng J, Wang J, Liu Q, et al. DAPT, a γ-secretase inhibitor, suppresses tumorigenesis, and progression of growth hormone-producing adenomas by targeting notch signaling. Front Oncol. 2019;9:809. https://doi.org/10.3389/fonc.2019.00809.

96. Huang RSF, Holmes BF, Powell C, et al. Delta-like protein 3 prevalence in small cell lung cancer and DLL3 (SP347) assay characteristics. Arch Pathol Lab Med. 2019;143:1373-1377. https://doi.org/10.5858/arpa.2018-0497-OA.

97. All B, Di Stefano I, Poma AM, et al. Prevalence of delta-like protein 3 in a consecutive series of surgically resected lung neuroendocrine neoplasms. Front Oncol. 2021;11:729765. https://doi.org/10.3389/fonc.2021.729765.
115. Muscarella LA, Mazza T, Fabrizio FP, et al. Neuroendocrine-related circulating transcripts in small-cell lung cancers: detection methods and future perspectives. *Cancers (Basel)*. 2021;13.

116. Lim S, Hong M, Kim SP, et al. P2.12-18 Prevalence of DLL3 expression and its prognostic role in extensive stage small cell lung cancer. *J Thorac Oncol*. 2019;14(10 Suppl):S820.

117. Fu X, Liu Z, Xiang L, et al. PD-L1 predicts poor prognosis in surgically resected limited stage small-cell lung cancer. *Cancer Manag Res*. 2020;12:10939-10948. https://doi.org/10.2147/CMAR.S260599.

118. Alcala N, Leblay N, Gabriel AAG, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nat Commun*. 2019;10:3407. https://doi.org/10.1038/s41467-019-11276-9.

119. Prieto T, Baldavira CM, Ab´saber A, et al. P47.11 DLL-3 and ASCL-1 expression emerge as promising therapeutic targets in high-grade neuroendocrine lung tumors: a preliminary study. *Clin Cancer Res*. 2019;25:6958-6966. https://doi.org/10.1158/1078-0432.CCR-19-1133.

120. Chauhan A, Kim JT, Weiss H, et al. Potentiating mTOR’s anti-neoplastic effects with rovalpituzumab tesirine in neuroendocrine tumors. *Pancreas*. 2018;47:335.

121. Mansfield AS, Hong DS, Hann CL, et al. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. *NPJ Precis Oncol*. 2021;5:74. https://doi.org/10.1038/s41698-021-00214-y.

122. Blackhall F, Jao K, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. *J Thorac Oncol*. 2021;16:1547-1558. https://doi.org/10.1016/j.jtho.2021.02.009.

123. Johnson ML, Zvirbule Z, Luktionov K, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. *J Thorac Oncol*. 2021;16:1570-1581. https://doi.org/10.1016/j.jtho.2021.03.012.

124. Goodrin AS, Hong DS, Hann CL, et al. A phase I study of rovalpituzumab tesirine in patients with relapsed or refractory small cell lung cancer. *Cancer Manag Res*. 2020;12:10939-10948. https://doi.org/10.2147/CMAR.S260599.

125. Alcala N, Leblay N, Gabriel AAG, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nat Commun*. 2019;10:3407. https://doi.org/10.1038/s41467-019-11276-9.

126. Prieto T, Baldavira CM, Ab´saber A, et al. P47.11 DLL-3 and ASCL-1 expression emerge as promising therapeutic targets in high-grade neuroendocrine lung tumors: a preliminary study. *Clin Cancer Res*. 2019;25:6958-6966. https://doi.org/10.1158/1078-0432.CCR-19-1133.

127. Chauhan A, Kim JT, Weiss H, et al. Potentiating mTOR’s anti-neoplastic effects with rovalpituzumab tesirine in neuroendocrine tumors. *Pancreas*. 2018;47:335.

128. Blackhall F, Jao K, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. *J Thorac Oncol*. 2021;16:1547-1558. https://doi.org/10.1016/j.jtho.2021.02.009.

129. Johnson ML, Zvirbule Z, Luktionov K, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. *J Thorac Oncol*. 2021;16:1570-1581. https://doi.org/10.1016/j.jtho.2021.03.012.

130. Goodrin AS, Hong DS, Hann CL, et al. A phase I study of rovalpituzumab tesirine in patients with relapsed or refractory small cell lung cancer. *Cancer Manag Res*. 2020;12:10939-10948. https://doi.org/10.2147/CMAR.S260599.

131. Aaron WH, Austin R, Barath M, et al. Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer. *Mol Cancer Ther*. 2019;18:C033-C033.

132. ClinicalTrials.gov. Study in Patients with Advanced Cancers Associated with Expression of DLL3 Who Have Failed Standard Available Therapy. https://clinicaltrials.gov/ct2/show/NCT04471727. Accessed September 26, 2021.